Justification of Chemotherapy Duration in Patients with Multiple and Pre-Extensive Drug Resistant Tuberculosis in the Russian Federation

The objective: to justify the optimal duration of chemotherapy with Lzd and Bdq by evaluating the long-term treatment outcomes in patients with multiple/pre-extensive drug resistant (MDR/preXDR) tuberculosis who interrupted treatment at different time points.

Subjects and Methods. 800 patients with MDR/preXDR tuberculosis were enrolled in the study, they were from all regions of the Russian Federation and they started a course of chemotherapy with regimens containing Lzd and Bdq in 2017-2018. All patients who interrupted their chemotherapy (124) were divided at 4 groups. Group 1-43 patients who received less than 90 doses, Group 2-37 patients who received from 91 to 180 doses, Group 3-39 patients who received from 181 to 270 doses, and Group 4-5 patients who received from 271 to 360 doses of anti-tuberculosis drugs.

Results. In Group 3, the effectiveness of reaching a favorable outcome during observation for 3-4 years made 53.8% in 21/39, which was comparable to the effectiveness of treatment with a 24-month course of chemotherapy (2017 – 58.0 and 2018 – 52.1%). The treatment duration of patients from Group 3 was additionally analyzed, the arithmetic mean of the number of administered doses makes 262 ± 15, which allowed recommending 9-month courses of chemotherapy.

1. Aksenova V.A., Klevno N.I., Kazakov A.V., Kovalevskaya E.B. Short course chemotherapy in children suffering from drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 2, pp. 34-39. (In Russ.)

2. Gayda A.I., Nikishova E.I., Maryandyshev A.O.. Postponed treatment outcomes of patients with multiple drug resistant tuberculosis who interrupted the course of treatment. Tuberculosis and Lung Diseases, 2014, no. 12, pp. 47-52. (In Russ.)

3. Gelmanova I.Yu., Ahmad Khan F., Becerra M.K., Zemlyanaya N A., Unakova I. A., Andreev Yu., Yedilbayev A.B., Krasnov V.A., Keshavjee S. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. Int. J. Tuberc. Lung Dis., 2015, vol. 19, no. 4, pp. 399-405. doi: 10.5588/ijtld.14.0415. PMID: 25859994.

4. Golubchikov P.N., Kruk E.A., Mishustin S.P., Petrenko T.I., Kudlay D.A. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 38-45. (In Russ.)

5. State Register of Medications (Website). (In Russ.) Available at: https://grls.rosminzdrav.ru (Accessed: 16.12.2022).

6. Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Russkikh A.E. Medications for short-course chemotherapy of drug resistant tuberculosis and their effect on the host. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 8, pp. 54-64. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-8-54-64.

7. Tikhonov A.M., Burakova M.V., Vaniev E.V., Romsanov V.V., Vasilyeva I.A. Efficiency of chemotherapy with bedaquiline in drug resistant pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 2, pp. 22-26. (In Russ.)

8. Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.A., Ekimenko A.M., Cherenkova M.A., Kudlay D.A. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)

9. Agyeman A.A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob., 2016, vol. 15, no. 1, pp. 41. Published 2016 Jun 22. doi:10.1186/s12941-016-0156-y.

10. Hatami H., Sotgiu G., Bostanghadiri N., Abadi S.S.D., Mesgarpour B., Goudarzi H., Migliori G.B., Nasiri M.J. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J. Bras. Pneumol., 2022, vol. 48, no. 2, pp. e20210384. doi: 10.36416/1806-3756/e20210384. PMID: 35649043; PMCID: PMC8836629.

11. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. C. Kuaban [et al.]. Int. J. Tub. Lung Dis., 2015, vol. 19, no. 5, pp. 517-524.

12. Koirala S., Borisov S., Danila E. еt al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021, vol. 27, no. 5, pp. 403-412. doi: 10.1016/j.pulmoe.2021.02.006. Epub 2021 Mar 19. PMID: 33753021.

13. Pai H., Ndjeka N., Mbuagbaw L., Kaniga K., Birmingham E., Mao G., Alquier L., Davis K., Bodard A., Williams A., Van Tongel M., Thoret-Bauchet F., Omar S.V., Bakare N. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect. Dis., 2022. vol. 22, no. 1, pp. 870. doi: 10.1186/s12879-022-07861-x. PMID: 36414938; PMCID: PMC9682840.

14. Russkikh A., Korotych O., Sereda Y., Samoilova A., Achar J., Yedilbayev A., Dara M., Vasilyeva I. Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study. Monaldi Arch. Chest Dis., 2021, vol. 91, no. 1. doi: 10.4081/monaldi.2021.1678. PMID: 33470087.

15. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis ‒ rapid diagnostics for tuberculosis detection, 2021 update. Geneva, World Health Organization, 2021. Licence: CC BY-NC-SA 3.0 IGO.

16. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva, World Health Organization, 2022. Licence: CC BY-NC-SA 3 IGO.